Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Mar 2016

Lee Samuel S, Kilvert Leah, Liu Hongqun, Trepanier Janie

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pilot Projects

Share to Polyethylene Glycols

Share to Proline

Share to Recurrence

Share to Ribavirin

Source

Identifiers

PMID: 26459137
DOI: 10.1016/j.dld.2015.08.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.PMID 26459137Read ↗

Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.Semantic proximity Read ↗

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil.Semantic proximity Read ↗

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.Semantic proximity Read ↗

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.Semantic proximity Read ↗

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.Semantic proximity Read ↗

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.Semantic proximity Read ↗

Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.Semantic proximity Read ↗

A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.Semantic proximity Read ↗

Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.Semantic proximity Read ↗

Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.Semantic proximity Read ↗

Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.Semantic proximity Read ↗

OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.